MRK : Summary for Merck & Company, Inc. Common St - Yahoo Finance

U.S. Markets closed

Merck & Co., Inc. (MRK)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
61.13+0.37 (+0.61%)
At close: 4:03 PM EST
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close60.76
Bid61.27 x 900
Ask62.45 x 300
Day's Range60.62 - 61.52
52 Week Range47.97 - 65.46
Avg. Volume10,639,530
Market Cap168.54B
PE Ratio (TTM)31.22
Earnings DateN/A
Dividend & Yield1.88 (3.07%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals16 hours ago

    Tech Data’s board gets more diverse with addition of former Merck executive

    Tech Data Corp. has doubled the number of women on its board of directors. Bridgette Heller, a member of the executive committee of French food products company Danone, was appointed to the Tech Data (TECD) board late last month. Diverse companies are more likely to have financial returns above their national industry medians, and are better able to win top talent and improve their customer orientation, according to management consulting firm McKinsey & Co.

  • Merck & Co., Inc. (MRK) Gets Coveted Approval For Keytruda
    Insider Monkey17 hours ago

    Merck & Co., Inc. (MRK) Gets Coveted Approval For Keytruda

    Individual lung cancer patients may soon be able to benefit from Keytruda, an immunotherapy drug from Merck & Co., Inc. (NYSE:MRK). The news comes after the confirmation by the New Jersey drug maker that it had gained a second priority review tag from the US Food and Drug Administration (FDA). Britain’s healthcare cost-effectiveness watchdog NICE has […]

  • Market Realist20 hours ago

    AbbVie’s Venclexta May Become Promising Multiple Myeloma Therapy

    AbbVie (ABBV) and Roche Holdings (RHHBY) have completed a Phase 1 trial evaluating the use of Venclexta as a therapy for multiple myeloma patients.